Seasoned dermatology and immunology executive brings more than 25 years of experience advancing and launching innovative therapies, including OPZELURA®, povorcitinib, ILUMYA®, ODOMZO®, REMICADE®, and STELARA® Dr. Patel to lead Palvella’s Medical Affairs organization, advancing scientific engagement, KOL collaboration, disease state awareness, and medical education for the Company’s QTORIN™ programs targeting serious, rare skin diseases, including microcystic lymphatic malformations and cutaneous venous malf ...